Clexane, the brand name for enoxaparin sodium, is a low-molecular-weight heparin (LMWH) used extensively as an anticoagulant in the prevention and treatment of thromboembolic disorders. Developed as a refinement of unfractionated heparin (UFH), enoxaparin offers several advantages, including predictable pharmacokinetics, a more favorable safety profile, and ease of administration without routine laboratory monitoring. This report provides a concise yet thorough examination of Clexane, covering its pharmacology, clinical indications, dosing, adverse effects, and place in modern therapy.

Pharmacology and Mechanism of Action

Enoxaparin is derived from porcine intestinal mucosal heparin by controlled chemical depolymerization, yielding fragments with a mean molecular weight of approximately 4,500 daltons. Like all heparins, its primary anticoagulant effect is mediated by binding to antithrombin III (ATIII), a natural inhibitor of coagulation factors. The LMWH-enoxaparin complex accelerates the inactivation of factor Xa to a greater extent than thrombin (factor IIa) due to its shorter chain length, which hinders simultaneous binding to both ATIII and thrombin. This results in an anti-Xa to anti-IIa activity ratio of about 3.6:1, conferring a more predictable anticoagulant response and reducing the risk of bleeding compared with UFH.

Subcutaneous administration of enoxaparin yields rapid and nearly complete absorption (bioavailability ~100%), with peak plasma anti-Xa activity occurring 3 to 5 hours after injection. The elimination half-life is approximately 4.5 hours, allowing once- or twice-daily dosing for most indications. Unlike UFH, enoxaparin does not significantly bind to plasma proteins, endothelial cells, or platelets, which contributes to its predictable dose-response relationship and lower incidence of heparin-induced thrombocytopenia (HIT).

Clinical Indications

Clexane is approved for a wide range of thrombotic conditions:

1. Prophylaxis of venous thromboembolism (VTE): In patients undergoing major orthopedic surgery (e.g., hip or knee replacement), general surgery, or those with acute medical illness and restricted mobility, enoxaparin 40 mg once daily (or 30 mg twice daily for orthopedic patients) effectively reduces the incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE). It is also used for VTE prophylaxis in surgical patients with cancer.
2. Treatment of acute DVT with or without PE: For established VTE, enoxaparin is administered at 1 mg/kg twice daily or 1.5 mg/kg once daily (based on clinical trial data), typically overlapping with warfarin or a direct oral anticoagulant (DOAC) until international normalized ratio (INR) targets are achieved. It is also a standard bridge therapy for patients requiring temporary interruption of oral anticoagulants.
3. Treatment of acute coronary syndromes (ACS): In patients with unstable angina or non-ST-segment elevation myocardial infarction (NSTEMI), enoxaparin 1 mg/kg twice daily (with dose adjustments for elderly or renally impaired patients) reduces the risk of death, myocardial infarction, and recurrent ischemia. In STEMI, it is used as an adjunct to thrombolytic therapy or percutaneous coronary intervention.
4. Anticoagulation in pregnancy: Enoxaparin is preferred over UFH for thromboprophylaxis and treatment of VTE during pregnancy due to its ease of use and lower risk of osteoporosis and HIT. Dosing is often weight-based and adjusted for renal function.

Dosing and Administration

Clexane is administered subcutaneously, usually in the abdominal area. Doses are based on indication, patient weight, and http://laliqua.es/) renal function due to its reliance on renal clearance. A dose reduction (e.g., 30 mg once daily for prophylaxis) is recommended in patients with severe renal impairment (creatinine clearance <30 mL/min). Elderly patients may require reduced doses for certain indications. Injection technique is important to avoid bruising; prefilled syringes with graduated markings facilitate accurate dosing.

Adverse Effects and Contraindications

The most significant adverse effect of enoxaparin is bleeding, ranging from minor injection-site hematomas to major hemorrhage (e.g., intracranial, retroperitoneal). Risk factors include high doses, renal impairment, concomitant use of antiplatelet agents or other anticoagulants, and recent surgery. Heparin-induced thrombocytopenia (HIT) is less common with enoxaparin than with UFH (incidence <1%) but can still occur; monitoring of platelet counts is recommended. Other side effects include injection-site pain, skin necrosis, hyperkalemia (due to aldosterone suppression), and rare allergic reactions. Osteoporosis is less likely with LMWHs compared with UFH in long-term use.

Contraindications include a history of heparin-induced thrombocytopenia, active major bleeding, severe uncontrolled hypertension, and known hypersensitivity to heparin or pork products. Use during pregnancy is generally safe (FDA category B), but breastfeeding requires caution.

Comparison with Other Anticoagulants

Enoxaparin remains a cornerstone in acute settings, especially where rapid onset and offset are needed, such as perioperative prophylaxis or bridging. Compared with UFH, it offers easier dosing, no need for activated partial thromboplastin time (aPTT) monitoring, and lower risk of HIT. Direct oral anticoagulants (e.g., rivaroxaban, apixaban) have replaced enoxaparin for many long-term indications due to oral administration and fixed dosing, but enoxaparin retains advantages in pregnant patients, patients with extreme body weight, those requiring parenteral therapy, and those with severe renal impairment (where some DOACs are contraindicated). In ACS, enoxaparin is sometimes preferred over UFH based on trial data showing reduced composite endpoints, though both remain in practice.

Special Populations

In patients with obesity, weight-based dosing is recommended for treatment but dosing for prophylaxis is not routinely adjusted; clinical judgment is required. In children, enoxaparin is used off-label for VTE treatment and prophylaxis, with anti-Xa monitoring to guide dosing. In the elderly, reduced renal function often necessitates dose adjustment, and careful monitoring for bleeding is essential.

Monitoring and Management

Routine coagulation monitoring is not required for most patients receiving enoxaparin. However, anti-Xa activity levels may be measured in special circumstances (e.g., pregnancy, renal insufficiency, morbid obesity, extremes of age) to ensure therapeutic concentrations (0.5–1.0 IU/mL for twice-daily treatment, 0.2–0.4 IU/mL for prophylaxis). Management of major bleeding involves discontinuation of enoxaparin and administration of protamine sulfate, which partially neutralizes its anti-Xa activity (1 mg protamine per 1 mg enoxaparin). Supportive measures include blood product transfusion and surgical intervention if needed.

Conclusion

Clexane (enoxaparin) is a well-established, reliable anticoagulant with a broad range of indications spanning prevention and treatment of VTE, management of ACS, and use in special populations such as pregnancy. Its predictable pharmacokinetics, ease of subcutaneous administration, and favorable safety profile have made it a mainstay in both hospital and outpatient settings. While newer oral anticoagulants continue to gain ground, enoxaparin remains indispensable in acute care and for patients requiring parenteral therapy. Clinicians must remain vigilant about bleeding risk, renal impairment, and the rare possibility of HIT, but when used appropriately, Clexane saves lives and reduces thrombotic morbidity worldwide.